Vertaling van "surveillance study for bupropion sustained-release " (Nederlands → Frans) :

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
A prospective safety surveillance study for Bupropion sustained-release in the treatment of depression.

40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of Bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.
12. Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al. Lateterm smoking cessation despite initial failure: an evaluation of Bupropion sustained release, nicotine patch, combination therapy, and placebo.

13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation.
13. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained release Bupropion, a nicotine patch or both for smoking cessation.

39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.
39. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA et al. Effects of sustained-release Bupropion among persons interested in reducing but not quitting smoking.

Zoals aangetoond werd in het programma van klinische studies, was er een mediane relatieve reductie met 97% van het PSA na maand 6 met Decapeptyl Sustained Release 22,5 mg.
Comme montré pendant les études cliniques, au 6 ème mois de traitement par Decapeptyl Sustained Release 22,5 mg, la diminution relative médiane du PSA était de 97%.

Studies bij dieren geven aan dat hogere doses Decapeptyl Sustained Release 22,5 mg geen andere effecten teweegbrengen dan de bedoelde therapeutische effecten op de geslachtshormoonspiegels en op het voortplantingsstelsel.
Des tests réalisés chez l’animal suggèrent qu’aucun autre effet que les effets thérapeutiques sur la concentration d’hormones sexuelles et sur l’appareil reproducteur n’est attendu avec des doses plus élevées de Decapeptyl Sustained Release 22,5 mg.